Michael Hedvat
Sanford-Burnham Institute for Medical Research
5 Papers
47 Citations
Michael Hedvat is an academic researcher from Sanford-Burnham Institute for Medical Research. The author has contributed to research in topics: Biology & Genetic enhancement. The author has an hindex of 5, co-authored 5 publications. Previous affiliations of Michael Hedvat include Virginia Commonwealth University.
Chat about Author
Papers
Role of Excitatory Amino Acid Transporter‐2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics
Keetae Kim,Seok-Geun Lee,Timothy P. Kegelman,Zhao-zhong Su,Swadesh K. Das,Rupesh Dash,Santanu Dasgupta,Paola M. Barral,Michael Hedvat,Michael Hedvat,Paul Diaz,John C. Reed,John L. Stebbins,Maurizio Pellecchia,Devanand Sarkar,Paul B. Fisher +15 more
TL;DR: The potential utility of the EAAT2 promoter is emphasized for developing both low and high throughput screening assays to identify novel small molecule regulators of glutamate transport with potential to ameliorate pathological changes occurring during and causing neurodegeneration.
393
Targeting Mcl-1 for the therapy of cancer
Bridget A. Quinn,Rupesh Dash,Belal Azab,Siddik Sarkar,Swadesh K. Das,Sachin Kumar,Regina A. Oyesanya,Santanu Dasgupta,Paul Dent,Steven Grant,Mohamed Rahmani,David T. Curiel,Igor P. Dmitriev,Michael Hedvat,Jun Wei,Bainan Wu,John L. Stebbins,John C. Reed,Maurizio Pellecchia,Devanand Sarkar,Paul B. Fisher +20 more
TL;DR: The multiple strategies that have been employed in targeting Mcl-1, as well as the significant potential these targeting agents provide in not only suppressing cancer growth, but also in reversing resistance to conventional cancer treatments are reviewed.
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.
Belal Azab,Rupesh Dash,Swadesh K. Das,Sujit K. Bhutia,Xue-Ning Shen,Bridget A. Quinn,Siddik Sarkar,Xiang-Yang Wang,Michael Hedvat,Michael Hedvat,Igor P. Dmitriev,David T. Curiel,Steven Grant,Paul Dent,John C. Reed,Maurizio Pellecchia,Devanand Sarkar,Paul B. Fisher +17 more
TL;DR: Evaluated the improved transgene delivery and efficacy of Ad.5/3 recombinant virus expressing melanoma differentiation associated gene‐7/interleukin‐24 (mda‐ 7/IL‐24), an effective wide‐spectrum cancer‐selective therapeutic and added the novel Bcl‐2 family pharmacological inhibitor Apogossypol derivative BI‐97C1 (Sabutoclax) significantly augmented the efficacy.
Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Michael Hedvat,Luni Emdad,Swadesh K. Das,Keetae Kim,Santanu Dasgupta,Shibu Thomas,Bin Hu,Shan Zhu,Rupesh Dash,Bridget A. Quinn,Regina A. Oyesanya,Timothy P. Kegelman,Upneet K. Sokhi,Siddik Sarkar,Eda Erdogan,Mitchell E. Menezes,Praveen Bhoopathi,Xiang-Yang Wang,Martin G. Pomper,Jun Wei,Bainan Wu,John L. Stebbins,Paul Diaz,John C. Reed,Maurizio Pellecchia,Devanand Sarkar,Paul B. Fisher,Paul B. Fisher +27 more
TL;DR: The isolation of Sabutoclax, an optically pure isomer of Apogossypol displaying superior efficacy and reduced toxicity is illustrated, illustrating the power of combining structure-based modeling with rational design to predict appropriate derivatives of lead compounds to be empirically tested and evaluated for bioactivity.
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity
Rupesh Dash,Belal Azab,Bridget A. Quinn,Xue-Ning Shen,Xiang-Yang Wang,Swadesh K. Das,Mohamed Rahmani,Jun Wei,Michael Hedvat,Paul Dent,Igor P. Dmitriev,David T. Curiel,Steven Grant,Bainan Wu,John L. Stebbins,Maurizio Pellecchia,John C. Reed,Devanand Sarkar,Paul B. Fisher +18 more
TL;DR: It is demonstrated that pharmacological inhibition of Mcl-1 expression with the unique Apogossypol derivative, BI-97C1, sensitizes human PCs to mda-7/IL-24–mediated cytotoxicity, thus potentially augmenting the therapeutic benefit of this combinatorial approach toward PC.